352 related articles for article (PubMed ID: 11010689)
1. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date; reopening of administrative record. Food and Drug Administration, HHS. Final rule; delay of effective date; reopening of administrative record.
Fed Regist; 2000 May; 65(86):25639-41. PubMed ID: 11010689
[TBL] [Abstract][Full Text] [Related]
2. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
Food and Drug Administration, HHS
Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
[TBL] [Abstract][Full Text] [Related]
3. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
Food and Drug Administration, HHS
Fed Regist; 2006 Nov; 71(218):66108-9. PubMed ID: 17099971
[TBL] [Abstract][Full Text] [Related]
4. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Dec; 64(232):67720-63. PubMed ID: 11010665
[TBL] [Abstract][Full Text] [Related]
5. Distribution of certain drug products by registered blood establishments and comprehensive hemophilia diagnostic treatment centers that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements and administrative procedures. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Oct; 73(197):59496-501. PubMed ID: 18985968
[TBL] [Abstract][Full Text] [Related]
6. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment.
Food and Drug Administration, HHS
Fed Regist; 2006 Jun; 71(114):34249-51. PubMed ID: 16795943
[TBL] [Abstract][Full Text] [Related]
7. The Prescription Drug Marketing Act of 1987.
Greenberg RB
Am J Hosp Pharm; 1988 Oct; 45(10):2118-26. PubMed ID: 3228083
[TBL] [Abstract][Full Text] [Related]
8. The prescription drug marketing act: a solution in search of a problem?
Angarola RT; Beach JE
Food Drug Law J; 1996; 51(1):21-55. PubMed ID: 11794352
[No Abstract] [Full Text] [Related]
9. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
[TBL] [Abstract][Full Text] [Related]
10. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Feb; 67(22):4904-7. PubMed ID: 11829025
[TBL] [Abstract][Full Text] [Related]
11. Medical devices; medical device distributor reporting--FDA. Final rule; notification of status under the Safe Medical Devices Act; confirmation of effective date.
Fed Regist; 1993 Sep; 58(168):46514-23. PubMed ID: 10128335
[TBL] [Abstract][Full Text] [Related]
12. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
[TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
[TBL] [Abstract][Full Text] [Related]
14. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
[TBL] [Abstract][Full Text] [Related]
15. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
16. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
[TBL] [Abstract][Full Text] [Related]
17. Medical devices; device tracking--FDA. Final rule; suspension of effective date; notification of status under the Safe Medical Devices Act; technical amendments.
Fed Regist; 1993 Aug; 58(156):43442-51. PubMed ID: 10127886
[TBL] [Abstract][Full Text] [Related]
18. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
[TBL] [Abstract][Full Text] [Related]
19. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
20. Medical devices; establishment registration and device listing for manufacturers and distributors of devices; companion to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 Sep; 63(188):51874-5. PubMed ID: 10185813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
